Blood transfusion instrumentation company Immucor (Nasdaq: BLUD) reported flat net income for the second fiscal quarter, while revenue ticked up.
Net income of $3.4 million on $27.2 million in sales in the second quarter, compared with net income of $3.4 million on $23.7 million in sales in the second quarter of last year. Earnings for the quarter were flat at 17 cents a share.
Through six months, Immucor had net income of $7.1 million on $54.5 million in sales, compared with net income of $6.4 million on $47 million in sales in the same period last year. Earnings through six months were 34 cents a share, up from earnings of 32 cents a share through six months of last year.
Commenting on the quarter, Edward Gallup, chairman and chief executive officer of Immucor, said, “Although we are disappointed by the second quarter results, we are proud of our accomplishments.”
During the second quarter, Gallup said Immucor successfully filed for CE marking 57 list A products, 53 list B products and in excess of 70 self declared products and received a recommendation for certification of CE marking. He also said demand for the firm’s new Galileo high volume instrument continues to be strong since its introduction to the European market.
Galileo clinical trial data has been collected in the US, added Gallup, who says Norcross, GA-based Immucor is in the process of preparing the submission to the FDA, which could occur in February.
Immucor: www.immucor.com
